article thumbnail

FDA Accepts sNDA for Furosemide (Furoscix) in Chronic Kidney Disease

HCPLive

The sNDA for furosemide seeks to expand the indication to include the treatment of edema due to fluid overload in patients with CKD, with a PDUFA date of March 6, 2025.

article thumbnail

Top 10 AI Cardiometabolic Startups to Watch in 2025 

Cardiometabolic Health Congress

This exciting overview highlights the top 10 AI-powered cardiometabolic startups poised to make significant impacts in 2025. Eko : AI-powered heart sound and EKG sensors paired with FDA-approved software for heart disease monitoring. Viz.ai : Uses AI to enhance care coordination and improve outcomes in cardiovascular care.

article thumbnail

5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC) 

Cardiometabolic Health Congress

Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. Disparities in care are also concerning, with diagnosed cardiometabolic diseases varying up to twofold among different racial and ethnic groups. In the U.S.,

CME 96
article thumbnail

Expansion of AstraZeneca’s Flagship Health Equity Program Healthy Heart Africa

DAIC

milla1cf Fri, 06/28/2024 - 19:07 June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa , its flagship health equity initiative, to target a broader range of non-communicable diseases (NCDs), including chronic kidney disease (CKD) as well as hypertension and cardiovascular disease.